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RED CELLS

Microvascular endothelial cells express a phosphatidylserine receptor:
a functionally active receptor for phosphatidylserine-positive erythrocytes
B. N. Yamaja Setty1 and Suhita Gayen Betal1
1Marian Anderson Comprehensive Sickle Cell Anemia Care and Research Center, Department of Pediatrics, Division of Research Hematology, Jefferson
Medical College, Thomas Jefferson University, Philadelphia, PA

Phosphatidylserine (PS)–positive erythrocytes adhere to endothelium and subendothelial matrix components. While
thrombospondin mediates these interactions, it is unknown whether PSassociated erythrocyte-endothelial adhesion occurs in the absence of plasma
ligands. Using ionophore-treated PSexpressing control HbAA erythrocytes,
we demonstrate that PS-positive erythrocytes adhered to human lung microendothelial cells in the absence of plasma
ligands, that this adhesion was enhanced
following endothelial activation with IL1␣, TNF-␣, LPS, hypoxia, and heme, and

that this adhesive interaction was selective to erythrocyte PS. We next explored
whether microendothelial cells express
an adhesion receptor that recognizes cell
surface–expressed PS (PSR) similar to
that expressed on activated macrophages.
We demonstrate constitutive expression
of both PSR mRNA and protein that were
up-regulated in a time-dependent manner
following endothelial activation. While
minimal PSR expression was noted on
unstimulated cells, endothelial activation
up-regulated PSR surface expression. In
antibody-blocking studies, using PSpositive erythrocytes generated either ar-

tificially via ionophore treatment of control erythrocytes or from patients with
sickle cell disease, we demonstrate that
PSR was functional, supporting PSmediated erythrocyte adhesion to activated endothelium. Our results demonstrate the existence of a novel functional
adhesion receptor for PS on the microendothelium that is up-regulated by such
pathologically relevant agonists as hypoxia, cytokines, and heme. (Blood. 2008;
111:905-914)

© 2008 by The American Society of Hematology

Introduction
The anionic phospholipid phosphatidylserine (PS), present exclusively in the inner leaflet of the plasma membrane of a normal cell,
is externalized following cell activation with both physiologic and
pathologic stimuli such as activation of blood platelets resulting
from vessel wall injury and cells that are undergoing apoptosis.1,2
PS exposure on the red cell surface occurs in patients with various
hemolytic anemias3-9 activating numerous pathobiologic processes,
of which one is red cell–endothelial cell adhesion.10,11 The mechanism(s) underlying this PS-mediated adhesion process is not well
defined. Interaction of PS with immobilized subendothelial matrix
thrombospondin has been documented.10 In addition, soluble
thrombospondin-mediated adhesion of PS-positive erythrocytes to
endothelium can occur via the constitutively expressed endothelial
vitronectin receptor (VnR).10 Whether PS-related erythrocyte adhesion to endothelium can occur in the absence of plasma ligands is
not known. In the present study, we explore this possibility, and
hypothesize that endothelial cells express novel adhesion receptor(s) that can interact directly with PS-positive erythrocytes in the
absence of plasma ligands. One such candidate is a receptor that
recognizes cell surface–expressed membrane-associated phosphatidylserine, referred hitherto as the phosphatidylserine receptor or
PSR, originally described by Fadok et al on the surface of activated
macrophages that recognizes and phagocytoses PS-positive apoptotic cells.12 In the present study, we explore whether microvascular
endothelial cells express this novel PS receptor. We demonstrate
that both PSR transcript and protein are expressed in human

microendothelial cells under basal conditions, and that expression
is up-regulated following cell activation with various physiologic
agonists. In further in vitro studies, we show that this receptor
protein is externalized following endothelial cell activation, and
that PSR is involved in PS-mediated erythrocyte adhesion to
activated endothelium.

Methods
Materials
For enzyme-linked immunosorbent assay (ELISA), flow cytometric analyses, Western blots, and adhesion-blocking studies, monoclonal and polyclonal antibodies against human antigens and isotope-matched negative
control antibodies were obtained from Cascade BioScience (Winchester,
MA), Immunotec (Beckman-Coulter, Miami, FL), R&D Systems (Minneapolis, MN), BD Biosciences (San Diego, CA), Chemicon International
(Temecula, CA), Serotec (Oxford, United Kingdom), Bio-Rad Laboratories
(Hercules, CA), Jackson ImmunoResearch Laboratories (West Grove, PA),
or Sigma Chemical (St Louis, MO). These reagents included either pure or
conjugated mouse monoclonal antibodies against PSR (clone 217), CD51
(␣-chain of the vitronectin receptor, clone AMF7), CD106 (VCAM-1,
clones 1G11, 51-10C9, and BBIG-V1), CD36 (the thrombospondin receptor, clone FA6.152), CD49d (␣-chain of the VLA4, clone HP2.1), CD62P
(P-selectin, clones CLB-Thromb/6, AK-6, and 9E1), CD54 (ICAM-1,
clones 84H10 and BBIG-I1), CD47 (integrin-associated protein or IAP,
clone BRIC126), CD239 (BCAM/LU, clone BRIC221), CD144
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(cadherin-5, clone TEA1/31), CD146 (alternately known as MCAM,
Muc-18, or S-endo, clone P1H12), ␤-tubulin (clone Tub2.1), isotypematched negative control antibodies (IgG isotype, clone 679.1Mc7, and
IgM isotype), annexin-V–FITC, a rabbit polyclonal antibody against human
PSR, horseradish peroxidase–conjugated goat anti–mouse IgG and anti–
rabbit IgG, Cy-3–conjugated goat anti–mouse IgM, phycoerythrin (PE)– or
fluorescein isothiocyanate (FITC)–conjugated goat anti–mouse IgG and
anti–rabbit IgG, and alkaline phosphatase–conjugated goat anti–mouse IgG
and IgM. While most experiments with anti-PSR have been done using the
Cascade antibody, both the anti-PSR antibody produced by Henson and
coworkers (Henson antibody; Fadok et al12) and the rabbit anti-PSR
polyclonal antibody also were used in representative flow cytometry and
adhesion experiments to compare and contrast the findings obtained with
the Cascade antibody. Tumor necrosis factor-␣ (TNF-␣), interleukin-1␣
(IL-1␣), the bacterial lipopolysaccharide (LPS), hemin, serine-L-phosphate,
serine-D-phosphate, L-␣-phosphatidylserine (PS), L-␣-phosphatidylcholine
(PC), the calcium ionophore A23187, and annexin-V (unconjugated pure,
33 kD; Sigma Chemical product no. A9460) were obtained from Sigma
Chemical, R&D Systems, or CN Biosciences (San Diego, CA). 51CrSodium chromate (14.8-44.4 GBq/mg) was obtained from PerkinElmer
Life Sciences (Norton, OH). Tissue culture supplies were procured from
Gibco Laboratories (Invitrogen, Carlsbad, CA) or Clonetics (Lonza,
Walkersville, MD).
Preparation of PS-positive erythrocytes
For the majority of experiments, PS-positive HbAA erythrocytes were
prepared from fresh blood drawn from adult control volunteers after
informed consent was obtained in accordance with the Declaration of
Helsinki. This study was reviewed and approved by the Institutional
Review Committee for the protection of human subjects at Thomas
Jefferson University. PS-positive red cells were prepared by treating these
control erythrocytes with A23187 as previously described.3 In brief, washed
erythrocytes (10% hematocrit in buffer-A [10 mM HEPES in calcium- and
magnesium-free Hanks balanced salt solution {CMF-HBSS}, pH 7.4]
containing 2.5 mM CaCl2) were incubated for 1 hour with 2.5 M A23187
and cells pelleted at 200g for 10 minutes. Following one wash with 2.5 mM
EDTA and 2 washes with 1% BSA in buffer-A, the cell pellets were
suspended in buffer-A to 50% hematocrit for labeling with 51Cr-sodium
chromate,13 and also for evaluation of cell-surface PS and other adhesion
markers by flow cytometry.14,15

Adhesion assays
For adhesion assays, both PS-positive (A23187-treated) and PS-negative
(untreated control) erythrocytes were labeled with 51Cr-sodium chromate,
and suspended to 10% hematocrit in buffer-A containing 1.25 mM CaCl2
and 0.75 mM MgCl2 in the absence of plasma and plasma-associated
soluble adhesion ligands. Radiolabeled erythrocytes containing 15% PSpositive cells were evaluated for their adhesive potential18 using HLMECs.
To assess direct interaction of PS with endothelial adhesion receptor(s),
adhesion assays were conducted in the absence of plasma and soluble
plasma ligands. To test whether endothelial activation modulated PSpositive erythrocyte adhesion, endothelial monolayers were subjected to
treatment either with hypoxia for 24 hours19 or with IL-1␣ (10 ng/mL),
TNF-␣ (10 ng/mL), or LPS (100 ng/mL) for 6 hours prior to adhesion. For
blocking studies with liposomes or serine phosphate isomers, erythrocytes
and endothelial cells were pretreated at 37°C for 45 minutes with the
desired agent prior to adhesion. In experiments evaluating the role of
specific endothelial adhesion receptors, endothelial monolayers were
pretreated for 45 minute with 40 g/mL of the appropriate monoclonal
antibody prior to adhesion. PSR antibodies used in this study have been
used extensively in studies assessing phagocytic recognition and removal of
PS-expressing apoptotic cells by macrophages, fibroblasts, and epithelial
cells.12,20,21 The rabbit polyclonal antibody against PSR from Sigma
Chemical recognizes specifically the peptide sequence 363 to 381 of human
PSR and has been shown to inhibit tethering of apoptotic Jurkat cells to
human umbilical vein endothelial cells.22 Other antibodies used in our
experiments have been previously shown to function as adhesion-blocking
reagents. To test adhesion specificity of PS, PS-positive erythrocytes were
incubated for 45 minutes in the presence or absence of annexin-V prior to
adhesion. Concentrations of annexin-V for blocking studies were selected
from preliminary dose-response experiments (n ⫽ 3) performed using
PS-positive erythrocytes (1 ⫻ 106) and annexin-V (1-40 g) with maximal
cloaking (95%-99%) observed at 8 g annexin-V. In final confirmatory
studies to assess the pathophysiologic relevance of PSR as a functional
adhesion receptor for PS-positive red cells, we performed additional
adhesion experiments using red cells from 9 individuals with HbSS disease,
whose red cells by flow cytometry demonstrated either low or relatively
high percentage of PS positivity (mean ⫾ SD: 1.0% ⫾ 0.8% vs
7.0% ⫾ 2.8%, respectively). All adhesion experiments were assayed in
triplicate with an intra-assay variability of less than 4%.
Analysis of endothelial PSR mRNA

Culture of endothelial cells and HT1080 cells
Human lung microvascular endothelial cells (HLMECs) were obtained
from Clonetics and cultured according to the manufacturer’s protocol. Cells
at passages 2 to 4 were used. Representative experiments also were
performed in human retinal capillary endothelial cells (HRCECs), which
were isolated, identified, and cultured in minimal essential medium
supplemented with 10% fetal calf serum.16 Cells from passages 6 to 8 were
evaluated in the experiments to be described. As a positive control for both
PSR antigen and mRNA analyses, we used HT1080 cells, a PSR-positive
tumor cell line12 of epithelial origin derived from human fibrosarcoma
(ATCC, Manassas, VA).
Preparation of liposomes
PC and PS liposomes were prepared as previously described.17 In brief,
appropriate amounts of PC (PC liposomes) or PS and PC (50:50, for PS
liposomes) were evaporated to semidryness, and reconstituted in buffer-A
containing 1.25 mM CaCl2 to 10 ⫻ in phospholipids. Following sonication
for 3 minute, the lipid vesicles were diluted in desired assay medium, and
extruded through a 1-m filter. The final concentration of total phospholipids in the assay medium was 30 M, and was similar to levels previously
used in adhesion experiments.11 These 1-m or smaller liposomes were
nontoxic to both red cells and endothelial cells as judged by morphologic
integrity and LDH release, and were stable for at least 24 hours at 37°C as
tested by flow cytometry for PS positivity.

Steady-state PSR mRNA levels were evaluated using reverse-transcriptase–
polymerase chain reaction (RT-PCR) analysis. Following incubation of
endothelial cells for various times in the presence or absence of the desired
agonist, total RNA was isolated using RNAqueous-4PCR kit (Ambion,
Austin, TX), and 2 g total RNA was reverse transcribed using Superscript-II reverse transcriptase (InVitrogen). The RT product then was
amplified using Taq DNA polymerase (Qiagen, Valencia, CA) and 0.8 M
PSR-specific primers. The PSR primers included 5⬘-CCA-GAA-GTT-CAAGTG-TGG-TGA-GGA-3⬘ (forward, nucleotides 403 through 426) and
5⬘-ACT-TTG-ATG-AGT-TCC-CTG-GGA-GTG-3⬘ (reverse, nucleotides
774 through 751), which yielded a PCR-product of 372 bp. The transcript
region selected for our RT-PCR analysis was similar to that previously
described for PSR mRNA in brain and spleen from rat and mouse.23 cDNA
for ␤-actin, a constitutively expressed transcript, was coamplified as an
endogenous control for quantitation of PSR mRNA. The ␤-actin–specific
primers (0.0375 M) used were 5⬘-ACG-TTG-CTA-TCC-AGG-CTG-TGCTAT-3⬘ (forward, nucleotides 439 through 462) and 5⬘-ACT-CCT-GCT-TGCTGA-TCC-ACA-TCT-3⬘ (reverse, nucleotides 1125 through 1102) yielding
a PCR-product of 687 bp. Both PSR and ␤-actin primers were selected
using the PrimerQuest Software (Integrated DNA Technologies, Coralville,
IA) and custom synthesized by Invitrogen. PCR-products were resolved on
a 1% agarose gel containing 0.4 g/mL ethidium bromide and analyzed
using a Bio-Rad Gel-Doc System. The relative ratio of test to endogenous
was determined for each treatment, and expressed as a ratio. For sequence
analysis, the amplified PCR fragment from the endothelial PSR transcript
was purified using Qiagen Gel Extraction kit and sequenced on a ABI
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PRISM Model 3100 Genetic Analyzer (Applied Biosystems, Foster City,
CA), and the sequence was matched with published PSR mRNA.
Analysis of endothelial PSR protein
PSR protein levels in endothelial cells were evaluated using a variety of methods
including Western blotting of total cellular proteins. Cell surface expression for
PSR used 2 complementary methods, that is, flow cytometry–based (cell
suspension) and fluorescence-based (intact cell monolayer) ELISA.
Analysis of PSR protein by Western blotting
Following incubation of endothelial cells for various times in the presence
or absence of the desired agonist, total cellular proteins were extracted with
Laemmli sample buffer. Total proteins (20 g) were denatured in sample
buffer, resolved using 8% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE), and transferred to nitrocellulose membranes.
Membranes were blocked with 5% milk protein in phosphate-buffered
saline containing 0.1% Tween-20, pH 7.4 (Tween-PBS), and probed
sequentially with a rabbit polyclonal antibody against PSR (1:2000
dilution) and HRP-conjugated goat anti–rabbit IgG (1:10 000 dilution)
diluted in Tween-PBS containing milk protein. After washing in TweenPBS, immunoreactive proteins were detected using a PerkinElmer ECL kit,
images scanned, and protein bands quantitated. Membranes were stripped
and reprobed for the constitutively expressed cytoskeletal protein ␤tubulin, as an endogenous control (to correct for loading differences).
Analysis of cell-surface expression of PSR protein by flow
cytometry
PSR protein expression on endothelial cells was evaluated by flow
cytometry following exposure of monolayers to the desired agonist for
6 hours. Endothelial cells were harvested by incubating washed monolayers
with 5 mM EDTA in CMF-HBSS. One million cells (suspension in 100 L
buffer-A containing 2.5 mM CaCl2 and 1% BSA) were incubated with
anti-PSR (2 g) or an isotype-matched negative control antibody for
30 minutes, an additional 30 minutes with appropriate second antibody
(1 g Cy3-labeled goat anti–mouse IgM or FITC-labeled goat anti–rabbit
IgG) in the dark at room temperature, and analyzed in a FACScan Flow
Cytometer (BD Immunocytometry Systems, San Jose, CA) at a flow rate of
200 to 500 cells/second. Data from 10 000 events were collected and
analyzed. Other endothelial adhesion receptors known to interact with red
cells including VCAM-1, CD36, VnR, P-selectin, and ICAM-1 also
were evaluated.
Analysis of cell-surface expression of PSR protein by
fluorescence ELISA
PSR protein expression on intact HLMEC monolayers was evaluated using
an ELISA-based assay similar to that previously described for other
endothelial adhesion receptors.19 In brief, following exposure to desired
agonist for 6 hours, endothelial monolayers were incubated for 90 minutes
with a mouse monoclonal antibody against PSR (10 g/mL, 200 L/well),
an additional 60 minutes with a goat anti–mouse IgM conjugated with
alkaline phosphatase (200 L/well, 1 to 50 dilution), and finally for
15 minutes with the phosphatase substrate Attophos (Promega, Madison,
WI). The reaction was terminated by addition of EDTA and product
measured fluorometrically (Millipore Cytofluor, Model 2350; Millipore,
Bedford, MA) with excitation and emission wavelengths set at 450 nm and
580 nm, respectively. All conditions were assayed in triplicate, with an
intra-assay variability of less than 4%. Background fluorescence was
measured with cells subjected to identical treatment in the presence of an
isotype-matched negative control antibody. In parallel experiments,
VCAM-1, CD36, and VnR, with an appropriate isotype-matched negative
control antibody, were evaluated to complement flow cytometric analyses.
Surface expression of PSR and other adhesion receptors also were
evaluated using HRCECs to complement data from human lung cells.

Figure 1. Effects of endothelial activation and modulators of PS interaction on
adhesion of PS-positive erythrocytes to human lung microvascular endothelial
cells. (A) Effects of endothelial activation on PS-positive erythrocyte adhesion to
HLMECs. Endothelial cells were subjected to activation either with hypoxia for
24 hours, or with IL-1␣ (10 ng/mL), TNF-␣ (10 ng/mL), or LPS (100 ng/mL) for
6 hours. Monolayers then were tested for their adhesive potential using either
PS-negative or PS-positive red cells prepared by treating control erythrocytes with
A23187. Adhesion of red cells to unactivated control endothelium (control) also is
shown. Values presented are the mean (⫾ SD) from 3 to 12 experiments. Adhesion of
test red cells to test endothelium was presented as fold change compared with
adhesion of PS-negative red cells to unactivated endothelial cells. *Values significantly different from the respective controls at P ⬍ .05 to P ⬍ .001. (B) Effects of
liposomes, serine phosphates, and annexin-V on erythrocyte adhesion to HLMECs.
Following activation of endothelial cells for 6 hours with IL-1␣ (10 ng/mL), cell
monolayers were preincubated in the presence or the absence of PC liposomes
(PCL), or PS liposomes (PSL) containing 30 M total phospholipid, 100 M
serine-L-phosphate (SLP), or 100 M serine-D-phosphate (SDP) for 45 minutes.
Monolayers then were tested for their adhesive potential in the presence of
appropriate modulator using red cells pretreated for 45 minutes with appropriate
inhibitor. In experiments assessing the effects of annexin-V (ANV), PS-positive
erythrocytes (used at 2.5% hematocrit) were pretreated with 300 g annexin-V/mL for
45 minutes, and then tested for their adhesive potential. Values presented are the
mean (⫾ SD) from 3 to 7 experiments. Adhesion of test red cells to test endothelium
was presented as fold change compared with adhesion of PS-negative red cells to
unactivated endothelial cells. *Values significantly different from the respective
controls at P ⬍ .05 to P ⬍ .01.

Statistical analysis
Statistical evaluation was performed using Sigmastat Statistical Package
(Jandel Scientific, San Rafael, CA). All results are presented as means
(⫾ SD). Multiple group comparison was done using either one-way
ANOVA (for data with normal distribution) or the Kruskal-Wallis test (for
data with nonnormal distribution). If the P value for this overall comparison
was statistically significant at P ⬍ .05, then group-wise comparison was
performed using Dunnett test or Dunn test. The unpaired or paired Student t
test, or the Mann-Whitney rank sum test on the medians, if the data showed
nonnormal distribution, was used to compare statistical significance
between 2 groups.

Results
Adhesion of PS-positive erythrocytes to lung microendothelial
cells under basal and activated conditions

As depicted in Figure 1A, adhesion of PS-positive erythrocytes to
lung microendothelial cells increased by approximately 2.5-fold
compared with PS-negative cells (n ⫽ 10, P ⬍ .01). This adhesion
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Figure 2. PSR mRNA levels in human lung microendothelial cells. (A) Time-dependent changes in PSR mRNA in
HLMECs. Endothelial cells were incubated in the presence of
IL-1␣ (10 ng per mL) for times indicated, and total RNA was
isolated and analyzed for mRNA for PSR using a semiquantitative RT-PCR assay. (B) Effects of cytokines and heme on
PSR mRNA expression in HLMECs. Endothelial cells were
incubated for 4 hours in the absence (lane 1) or presence of
10 ng/mL IL-1␣ (lane 2), 10 ng/mL TNF-␣ (lane 3), or 100 M
heme (lane 4) and then analyzed for PSR mRNA. RT-PCR
product of PSR mRNA from unactivated HT1080 cells (used
as a positive control for PSR expression) is shown in lane 5
for comparison. ␤-Actin mRNA was coamplified with PSR
mRNA as an endogenous control for quantitation. The RTPCR products of PSR mRNA (372-bp band) and ␤-actin
mRNA (687-bp band) from a representative experiment are
shown. (C) Densitometric readings of the ratio between PSR
and ␤-actin messages. Values, presented as fold-change
relative to the corresponding media control, are the means
(⫾ SD) from 3 different experiments.

was further enhanced by 2.5- to 8-fold following activation of
endothelial cells with agonists such as IL-1␣, TNF-␣, LPS, or
hypoxia (n ⫽ 3 to 12, P ⬍ .05 to P ⬍ .001). Cell activation had no
significant effect on PS-negative erythrocyte adhesion to endothelial cells. As shown in Figure 1B, to assess specificity of PSmediated adhesion, we evaluated the effects of annexin-V (used to
cover surface PS), PS liposomes and serine-L-phosphate (competitors for PS binding), PC liposomes (control for PS liposomes), and
serine-D-phosphate (control for serine-L-phosphate) on adhesion.
Results demonstrate that preincubation of red cells with annexin-V
or pretreatment of red cells and endothelial cells with PS liposomes
inhibited adhesion of PS-positive erythrocytes to activated endothelial cells by 52% and 57%, respectively (P ⬍ .01), while PC
liposomes had no effect. While pretreatment of PS-positive red
cells and endothelial cells with serine-L-phosphate inhibited erythrocyte adhesion to activated endothelial cells by 52% (P ⬍ .01),
serine-D-phosphate had no effect. Adhesion of PS-positive red cells
to unactivated endothelial cells also was inhibited by 31% and 28%
with annexin-V and PS liposomes, respectively (P ⬍ .05). None of
the PS modulators tested had any significant effect on PS-negative
erythrocyte adhesion to activated endothelial cells. These studies
demonstrate that the interaction between erythrocytes and endothelial cells is PS specific, and suggest that novel adhesion receptors
recognizing PS-positive erythrocytes are expressed on activated
endothelium.

protein in endothelial cells by immunoblotting total cellular
proteins with a PSR-specific antibody. Endothelial PSR protein
levels mirrored steady-state mRNA levels. Basal PSR protein
expression that was detected in unactivated control endothelial
cells (Figure 3B lane 1) was up-regulated in a time-dependent
manner following activation with IL-1␣ with maximal stimulation
of approximately 175% noted over baseline at 6 hours (Figure
3A,B lane 2, 3C). Other activators including TNF-␣ and hemin,
which up-regulated PSR mRNA in endothelial cells, also enhanced
PSR protein expression in these cells by 89% and 58%, respectively, over baseline (Figure 3B lanes 3,4, 3C). These studies
demonstrate that lung microendothelial cells express both PSR
transcript and protein constitutively, and that their expression is
up-regulated by cell activation.

Lung microendothelial cells express PSR mRNA and protein

We next assessed whether PSR (previously reported to be expressed on activated macrophages) was present in endothelial cells.
Using RT-PCR, we demonstrate the presence of PSR mRNA in
total cellular RNA from unstimulated control human lung microvascular endothelial cells (Figure 2B lane 1). Identity of the PCR
product was confirmed by sequence analysis, which showed 100%
homology to this region in the published PSR mRNA sequence.
Treatment of endothelial cells with IL-1␣ (10 ng/mL) up-regulated
PSR mRNA in a time-dependent manner with maximal levels
(⬃ 3-fold increase) noted at 4 hours following cell activation
(Figure 2A,B lane 2, 2C). Activation of endothelial cells with
TNF-␣ (10 ng/mL) and hemin (100 M) also up-regulated PSR
mRNA by 138% and 100%, respectively (Figure 2B lanes 3,4, 2C).
We next evaluated whether PSR mRNA was translated to PSR

Figure 3. PSR protein expression by human lung microendothelial cells.
(A) Time-dependent expression of PSR protein in HLMECs. Endothelial cells were
incubated in the presence of IL-1␣ (10 ng per mL) for times indicated, and total
proteins were isolated and analyzed for PSR protein using Western blots as
described. (B) Effects of cytokines and heme on PSR protein expression in HLMECs.
Endothelial cells were incubated for 6 hours in the absence (lane 1) or presence of
10 ng/mL IL-1␣ (lane 2), 10 ng/mL TNF-␣ (lane 3), or 100 M heme (lane 4) and then
analyzed for PSR protein. Total protein extract from unactivated HT1080 cells (used
as a positive control for PSR protein expression) is shown in lane 5 for comparison.
Equal protein loading was checked by reprobing the stripped immunoblots for
␤-tubulin protein. PSR and ␤-tubulin protein bands from a representative immunoblasts are shown. Vertical lines between lanes have been inserted to indicate
repositioned gel lanes. (C) Densitometric readings of the ratio between PSR and
␤-tubulin proteins: Values are the means (⫾ SD) from 3 different experiments.

Figure 4. Surface expression of PSR protein on human lung microendothelial cells: analysis by flow cytometry. Following incubation of endothelial cells for 6 hours in
the absence (left column) or presence of IL-1␣ (10 ng/mL, middle column) or TNF-␣ (10 ng/mL, right column), cells were harvested, labeled with desired test antibody or an
equivalent amount of an isotype-matched negative control, and analyzed by flow cytometry as detailed. Endothelial cells labeled with mouse monoclonal antibody against PSR
from Cascade Bioscience (Bi-iii), Dr Henson’s laboratories (Ci-iii), and a rabbit polyclonal antibody against PSR from Sigma Chemical (Di-iii) are shown. Results presented are
from a representative experiment repeated 4 to 6 times with similar results. Endothelial cells labeled with appropriate isotype-matched negative control antibodies are shown in
panels Ai-iii. The red and blue lines are the negative histogram profiles for the rabbit polyclonal and mouse monoclonal antibodies, respectively. Markers M1 and M2 are the
positive histogram regions for the anti-PSR monoclonal and polyclonal antibodies that were set up with endothelial cells labeled with appropriate isotype-matched negative
control antibodies. Percentage marker-positive cells is shown in each panel. HT1080 cells analyzed concomitantly demonstrated 71% to 79% positivity with all
3 antibodies.ENDOTHELIAL CELLS AND PHOSPHATIDYLSERINE RECEPTOR
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Cell-surface expression of PSR protein on lung
microendothelial cells

While immunoblotting of total cellular proteins demonstrated
the presence of PSR protein in endothelial cells, these experiments did not reveal whether this receptor protein was present
on the cell surface. Using complementary flow cytometric– and
ELISA-based assays, with IL-1␣ and TNF-␣ as agonists, and
both monoclonal (Cascade anti-PSR and Henson antibody) and
polyclonal (Sigma Chemical) anti-PSR, we next explored
whether PSR protein was expressed on the endothelial surface.
Results presented in Figure 4Bi demonstrate that while endothelial cells were minimally positive for PSR in the unactivated
state (3.3% cells), significant numbers of cells acquired PSR
positivity following activation with IL-1␣ or TNF-␣ (⬃ 20%30% cells, Figure 4Bii,iii). Similar PSR expression profiles also
were observed when the second mouse monoclonal anti-PSR
antibody (Henson antibody, Figure 4Ci-iii) and a PSR polyclonal antibody (Figure 4Di-iii) were used in flow cytometric
analysis. These findings also were confirmed using a complemen-

tary ELISA-based assay using intact cell monolayer activated
with IL-1␣ or TNF-␣ (⬃ 3-fold induction with both modulators,
Figure 5A). The agonists LPS and hypoxia also induced cell
surface PSR expression by 1.6- and 4-fold, respectively (Figure
5A). Representative adhesion markers that are constitutively
expressed (VnR), induced (VCAM-1), and up-regulated (CD36)
in endothelial cells also were evaluated concomitantly in both
flow cytometric– and ELISA-based analyses for comparison
with the PSR expression profile. As shown in Table 1 and Figure
5A, no significant changes in the constitutively expressing VnR
were noted in response to activation by the cytokines IL-1␣ or
TNF-␣. While both cytokines induced the expression of VCAM-1
on the lung microendothelium, no significant changes in CD36
expression were noted at the concentration of agonists used in
both flow cytometric–based (Table 1) and ELISA-based (Figure
5A) assays. A similar adhesion molecule expression profile was
noted in intact human retinal capillary endothelial cell monolayers. These studies demonstrate that while PSR is minimally
expressed constitutively on the cell surface, its expression is
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Figure 5. Surface expression of PSR protein and other
adhesion markers on human microendothelial cells: analysis by fluorescence ELISA. (A) Expression of PSR protein on
intact HLMECs. Human lung microendothelial cells were subjected to activation for 6 hours with IL-1␣ (10 ng/mL), TNF-␣
(10 ng/mL), or LPS (100 ng/mL), or for 24 hours with hypoxia, and
then assessed for surface PSR using an ELISA-based assay.
Expression profiles of VCAM-1, CD36, and the vitronectin receptor (VnR) in response to endothelial activation are also shown.
Values presented are the mean plus or minus SD from 4 to
6 experiments. (B) Expression of PSR protein on intact HRCECs.
Human retinal capillary endothelial cells were subjected to activation for 6 hours with IL-1␣ (10 ng/mL), TNF-␣ (10 ng/mL), or LPS
(100 ng/mL), or for 24 hours with hypoxia, and then assessed for
surface PSR using an ELISA-based assay. Expression profiles of
VCAM-1, CD36, and the vitronectin receptor (VnR) in response to
endothelial activation are also shown. Values presented are the
mean plus or minus SD from 3 experiments.

Table 1. Adhesion molecules expressed on human lung microvascular endothelial cells
Marker
CD51

Positivity
MCF

PSR

Positivity
MCF

CD36

Positivity
MCF

ICAM-1

Positivity
MCF

VCAM-1

Positivity
MCF

*P-selectin

Positivity

Unstimulated endothelial
cell control

IL-1␣–activated
endothelial cells

87 ⫾ 9%

90 ⫾ 8%

340 ⫾ 28
5 ⫾ 0.5%
38 ⫾ 3
33 ⫾ 18%
116 ⫾ 29
38 ⫾ 7%
268 ⫾ 33
7 ⫾ 3%
45 ⫾ 8
Not detected

induced on microendothelial cells following activation with
physiologically relevant agonists.
PSR supports adhesion of PS-positive erythrocytes to lung
microendothelial cells

389 ⫾ 3
26 ⫾ 3%
175 ⫾ 21
30 ⫾ 16%
115 ⫾ 43
92 ⫾ 3%
607 ⫾ 9
53 ⫾ 16%
322 ⫾ 97
Not detected

MCF
Besides being characterized to be positive for acetylated LDL receptor, Factor
VIII-related antigen and CD31 by the manufacturer, the lung endothelial cells used in the
study were identified by flow cytometric analyses to be 90 to 98% positive for constitutively
expressing antigens including CD146, and CD144 (two endothelial-specific antigens).
Following incubation of endothelial cells for 6 hours in the absence, or presence of IL-1␣
(10 ng/mL), cells were harvested, labeled with desired test antibody or an equivalent
amount of an isotype-matched negative control, and analyzed by flow cytometry as
detailed. Values presented are the means (⫾ SD) from 4 experiments. MCF, mean cell
fluorescence, is a measure of receptor density per cell. *While P-selectin expression was
undetectable under the experimental conditions described, P-selectin-positivity was noted
on endothelial cells activated with A23187 for 30-minutes (see the results section for
details). Multiple monoclonal antibodies were employed to identify the expression of
ICAM-1 (clones 84H10, and BBIG-I1), VCAM-1 (clones 1G11, 51-10C9, and BBIG-V1),
and P-selectin (clones CLB-Thromb/6, and AK-6). Similar expression profiles of adhesion
markers were noted on the endothelial surface with different monoclonal antibodies.
Results shown for ICAM-1, and VCAM-1 were obtained with clones 84H10, and 51-10C9,
respectively.

To assess the potential linkage between PSR expression and
functional adhesion, we performed concomitant adhesion assays in
the presence of PSR-specific antibodies initially using ionophoreactivated HbAA red cells. As depicted in Figure 6, while no
significant changes in adhesion to unactivated endothelium was
noted, anti-PSR inhibited PS-positive erythrocyte adhesion to
activated endothelium by 45% (n ⫽ 4, P ⬍ .01). Similar differential inhibitory effects were also observed with the Henson antibody
and the polyclonal anti-PSR antibody. Since multiple endothelial
receptors support erythrocyte adhesion, it became necessary to
identify the adhesion molecules expressed on the surface of the
cells that were integral to these experiments (eg, IL-1␣–stimulated
lung microvascular endothelial cells and the A23187-treated control HbAA erythrocytes). As depicted in Table 1, IL-1␣–activated
lung microendothelial cells expressed all adhesion receptors known
to interact with red cells with the exception of P-selectin (CD62P).
As shown in Table 2, among the red cell adhesion markers
evaluated, only PS showed both qualitative and quantitative
differences on the ionophore-treated HbAA red cell surface compared with untreated control erythrocytes. In adhesion experiments
(n ⫽ 4-6), preincubation of endothelial cells with anti-VnR, antiCD36, anti–VCAM-1, anti–ICAM-1, or isotype-matched negative
control antibodies (IgG or IgM) had no significant effects on either
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have done in previous studies.5 As shown in Figure 7, while the
anti-PSR polyclonal antibody had no significant effect on either
unstimulated or IL-1␣–stimulated adhesion of low-percentage
PS-positive HbSS erythrocytes to microvascular endothelium (panel
A), a significant inhibition in adhesion of HbSS erythrocytes
containing high-percentage PS-positive cells was noted to IL-1␣–
activated microendothelial cells (65% ⫾ 32% inhibition of agonistinduced adhesion, P ⫽ .05, panel B). These findings taken together
demonstrate that PSR supports PS-mediated erythrocyte adhesion
to IL-1␣–activated endothelium in the absence of serum or
plasma-associated adhesinogenic ligands and that the adhesion
occurs with PS-expressing cells generated under both artificial and
pathophysiologic circumstances.
Figure 6. Effects of antibodies against PSR and other endothelial adhesion
markers on PS-positive erythrocyte adhesion to human lung microendothelial
cells. Following incubation of endothelial cells for 6 hours in the presence or absence
of IL-1␣ (10 ng/mL), cell monolayers were pretreated with antibodies against desired
adhesion molecule at 40 g/mL, or an equivalent amount of an isotype-matched
negative control immunoglobulin (IgG or IgM) for 45 minutes. The monolayers were
then tested for their adhesive potential using PS-positive red cells with 15% PS
positivity prepared by treating control erythrocytes with A23187. These adhesion
assays were performed using red cells at 10% hematocrit in the absence of plasma
and plasma-associated soluble adhesion ligands. Results presented are the mean
(⫾ SD) from 3 to 7 experiments. Adhesion of test red cells to test endothelium was
presented as fold change compared with adhesion of PS-negative red cells to
unactivated endothelial cells. *Values significantly different from the respective
medium control or the IgM control at P ⬍ .01. Please note that to test CD62P or
P-selectin–mediated adhesion, endothelial cells were subjected to activation with
A23187 for 30 minutes, pretreated with anti-CD62P for 45 minutes, and then
assessed for their adhesinogenic potential with PS-positive erythrocytes (see legend
to Table 1 and “Results” for additional details).

basal or IL-1␣–stimulated adhesion. While CD62P expression was
undetectable under the experimental conditions described (ie,
IL-1␣ activation), P-selectin positivity was noted following endothelial activation with A23187 (160 ⫾ 140 vs 400 ⫾ 180 fluorescence units, n ⫽ 4, by ELISA with unstimulated and A23187
treated, respectively). To complete these analyses, we therefore
pretreated A23187-activated endothelial cells with anti-CD62P,
and demonstrate that this antibody had no significant effect on
PS-mediated erythrocyte adhesion (Figure 6). In final adhesion
experiments, we evaluated erythrocytes from patients with sickle
cell disease (HbSS genotype) with various levels of PS positivity
ranging from 0.3% to 11% dividing them into 2 experimental
groups including low versus high PS-positive HbSS erythrocytes
(1.0% ⫾ 0.8% vs 7.0% ⫾ 2.8% positivity, P ⬍ .02, Table 2) as we

Discussion
Our results demonstrate that human lung microendothelial cells
express both mRNA and protein for PS receptor under basal
conditions, and that expression of this receptor is up-regulated
following endothelial activation. While minimally expressed on the
cell surface under basal conditions, surface expression of PSR is
up-regulated following cell activation by a variety of pathophysiologic agonists including IL-1␣, TNF-␣, LPS, heme, and hypoxia.
In additional experiments, we demonstrate that PSR expressed on
the cell surface is functional, supporting the direct adhesion of
PS-positive erythrocytes to activated microendothelium.
PSR, originally described by Fadok et al, is expressed on the
surface of activated macrophages,12 and also present constitutively
on the surface of fibroblasts and epithelial cells,12 with recent
studies also documenting nuclear localization in fibroblasts.24 It is
not expressed by the circulating cellular elements of blood
including neutrophils, lymphocytes, monocytes, and erythrocytes.12 PSR, expressed on both phagocytes (macrophages) and
nonphagocytes (fibroblasts and epithelial cells), appears to mediate
phagocytic recognition and removal of PS-expressing apoptotic
cells,12,20,21,25 although there remains some controversial evidence
regarding this function. PSR plays an essential role in development
and differentiation of multiple organs during embryogenesis. Using
PSR knockout mouse models, recent studies have demonstrated
that PSR disruption leads to growth retardation and defects in
embryonic organogenesis and perinatal lethality presumed to be
due to ineffective apoptotic cell phagocytosis, although this has

Table 2. Adhesion molecules expressed on control erythrocytes made artificially PS-positive and on erythrocytes from patients with sickle
cell disease
Erythrocytes from control donors
Marker

Untreated (n ⴝ 4)

*A23187-treated erythrocytes
diluted with untreated RBCs (n ⴝ 4)

Erythrocytes from patients with sickle cell disease
†Low PS group (n ⴝ 4)

†High PS group (n ⴝ 5)

CD36

Positivity

Not present

Not present

0.5 ⫾ 0.5%

1.4 ⫾ 1.7%

VLA4

Positivity

Not present

Not present

0.03 ⫾ 0.06%

0.03 ⫾ 0.06%

PS

Positivity

⬍ 0.3%

15%

1.0 ⫾ 0.8%

CD47 (IAP)

Positivity; MCF

100%; 629 ⫾ 15

100%; 630 ⫾ 5

99 ⫾ 1%; 698 ⫾ 52

99 ⫾ 1%; 721 ⫾ 41

CD239 (BCAM/LU)

Positivity; MCF

23 ⫾ 16%; 305 ⫾ 47

20 ⫾ 13%; 300 ⫾ 32

44 ⫾ 9%; 414 ⫾ 12

21 ⫾ 16%; 389 ⫾ 79

††7.0 ⫾ 2.8%

Cell-surface PS and other potential erythrocyte adhesion markers were evaluated using 2-color flow cytometry and employing anti-glycophorin A as a marker for red cells.
Values presented are the mean (⫾ SD). Mean cell fluorescence (MCF) is a measure of receptor density per cell. Changes (positivity or MCF) noted with CD47 or CD239
between the control and A23187-treated erythrocyte were not significantly different from each other. The “low” PS sickle cell group is compared with the “high” PS sickle cell
group to demonstrate that the adhesion marker differences between these two HbSS groups was confined to significant differences in PS positivity.
IAP indicates integrin associated protein; and BCAM/LU, basal cell adhesion molecule/Lutheran protein.
*PS-positive red cells were prepared by treating control HbAA erythrocytes with A23187 and diluted with untreated red cells to obtain a cell suspension containing 15% PS
positivity.
†Erythrocytes from patients with sickle cell disease (HbSS genotype) were divided into 2 experimental groups including low PS and high PS groups based on percent PS
positivity as in our previous study.5
††P ⬍ .02 compared to low PS group.
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Figure 7. Effects of rabbit polyclonal antibody against PSR
on sickle erythrocyte adhesion to human lung microendothelial cells. Following incubation of endothelial cells for 6 hours in
the presence or absence of IL-1␣ (10 ng/mL), cell monolayers
were pretreated with rabbit polyclonal antibody against PSR (at
20 g/mL) for 30 minutes. The monolayers were then tested for
their adhesive potential using red cells from patients with sickle
cell disease (HbSS genotype). Adhesion assays were performed
using red cells at 10% hematocrit in the absence of plasma and
plasma-associated soluble adhesion ligands. Panels A and B
represent adhesion of HbSS erythrocytes with low PS positivity
(1.0% ⫾ 0.8% positivity) and high PS positivity (7.0% ⫾ 2.8%
positivity), respectively. Results presented are the mean (⫾ SD)
from 4 (A) or 5 (B) experiments. Adhesion of sickle red cells to test
endothelium was presented as fold change compared with
adhesion of control red cells to unactivated endothelial cells.
*P ⫽ .05 compared with the IL-1␣ control.

been recently questioned.26-29 PSR appears to be a glycosylated
protein with an apparent molecular size of 70 kDa12 and contains a
type II transmembrane domain, a potential intracellular tyrosine
phosphorylation site, and an extracellular domain containing runs
of serines (which could be involved in protein O-glycosylation)
and runs of basic amino acids lysine and arginine that could provide
potential binding sites for the anionic phospholipid PS.12 While
recent studies have also identified multiple nuclear localization
signals in the PSR sequence,24 a physiologic role for nuclear PSR
has yet to be elucidated. In the present study, we found that the
endothelial PSR migrated as a protein with a molecular size of
approximately 70 kDa. While we observed both basal and upregulated expression of endothelial PSR, surface expression was
noted mainly on activated endothelium using both polyclonal and
monoclonal antibodies. A recent study also documented constitutive expression of PSR in a macrovascular endothelium,22 and
showed that PSR mediated tethering of apoptotic Jurkat cells to
endothelial cells.22 In the present study, we have characterized PSR
expression at both mRNA and protein level in pathologically
relevant human pulmonary microvascular endothelium. We have
also used complementary methods (Western blotting, flow cytometry, and ELISA assays) and also both polyclonal and monoclonal
antibodies to characterize PSR protein. In addition, we have
demonstrated that endothelial activation by IL-1␣, TNF-␣, LPS,
heme, and hypoxia up-regulated surface expression of PSR.
The findings that surface PSR expression occurred mainly on
the activated endothelium and that pretreatment of activated
endothelial cells with anti-PSR antibody inhibited adhesion of
PS-positive erythrocytes in the absence of plasma or soluble
plasma adhesion ligands demonstrate that endothelial PSR supports
PS-mediated direct interaction of erythrocytes to activated microendothelium. PSR is very unlikely to be involved under basal
unstimulated conditions since PSR does not appear to be constitutively expressed on the cell surface, with the antibody-blocking
experiments corroborating the null effect. These results also
implicate at least one more additional non–PSR-associated pathway by which PS-positive cells interact directly with activated
endothelial cells in the absence of plasma ligands. Existence of a
non–PSR-mediated adhesion pathway was also suggested by the
findings that PS-positive erythrocytes interacted with unactivated
control endothelial cells and that this basal adhesion was not
affected by pretreatment of endothelial cells with anti-PSR prior to
adhesion. Since previous studies demonstrated that erythrocytes
from pathologic milieu interact, either directly or indirectly via
plasma ligands, with CD36,30 VnR,30,31 VCAM-1,32 ICAM-1,33 and
P-selectin34 (also reviewed in references Frenette35; Parise and

Telen36; Stuart and Nagel37), and since human lung microendothelial cells express these adhesion molecules either constitutively or
following activation (Table 1), we explored the possible involvement of these receptors in the direct adhesion of PS-positive
erythrocytes to human lung microendothelial cells. Antibodyblocking studies (Figure 6) suggested that these latter endothelial
receptors are not involved. In our adhesion experiments, we
initially used PS-positive erythrocytes prepared by activating
control HbAA erythrocytes with the calcium ionophore A23187.
Use of HbAA control cells obviated the involvement of the
adhesion markers VLA4 and CD36 that are also expressed with PS
on a subset of young erythrocytes (stress reticulocytes) in patients
with hemolytic anemias including sickle cell disease.5,32,38-40 While
other adhesion molecules including CD47 and B-CAM/LU are also
present on control erythrocytes,41,42 levels (both receptor positivity
and density) of these receptors did not change following activation
of red cells with the ionophore. Erythrocyte-endothelial interactions described in this study appeared to be mediated, in part, via
erythrocyte PS, since pretreatment of PS-positive erythrocytes with
annexin-V, or preincubation of erythrocytes and/or endothelial
cells with PS liposomes, or serine-L-phosphate inhibited adhesion
(Figure 1B). In contrast, PC liposomes and serine-D-phosphate had
no effect on this process.
Erythrocytes from patients with several hemolytic anemias
including sickle cell disease (SCD),3-5 thalassemia,6 malaria,7 and
chronic renal failure8,9 are positive for PS with levels ranging from
0.5% to more than 10%, and exhibit increased adhesiveness to
endothelium, with our previous published data documenting a
significant positive correlation between percentage sickle red cell
PS positivity and adhesion where enhanced erythrocyte-endothelial
adhesion was noted in the high PS-positive group (mean percentage positivity at 5.6%).5 In the present in vitro study, we also note
that PS-mediated erythrocyte adhesion occurs at similar levels of
PS positivity (mean percentage positivity at 7%), and that a
polyclonal antibody against PSR significantly inhibited this adhesion (Figure 7). Erythrocyte adhesion to endothelium correlates
with disease severity in patients with SCD,18 and is a major
etiologic factor in the pathogenesis of the vaso-occlusive or painful
crisis with long-term effects including chronic organ dysfunction
leading to increased morbidity and mortality.37,43 Cell-surface
expression of PSR occurred on the microendothelium following
activation of cells in vitro with agonists such as IL-1␣, TNF-␣,
heme, and hypoxia, agonists that are all pathologically relevant in
patients with sickle cell disease.44-48 Evidence also suggests both
chronic and acute endothelial activation in these patients as
documented by elevated levels of soluble VCAM-1, E-selectin, and
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ICAM-1 by many investigators including results from our laboratories.49-53 It is not known whether in vivo PSR expression occurs
under the influence of agonists that caused PSR expression under
the in vitro conditions described here, and whether red cell
PS-endothelial PSR adhesion occurs in the microvasculature in
such pathologic conditions as SCD and malarial infection where
such adhesion could influence disease pathology. Further studies
are required in appropriate animal models such as the transgenic
sickle mouse to delineate further the relevance of this novel
endothelial receptor in the process of in vivo cell-cell adhesion.
An interesting observation made by several investigators related
to PSR is its involvement in mediating anti-inflammatory responses
in numerous experimental models.12,23,25 Ligation of PSR with
apoptotic cells through PS or PS liposomes up-regulated the
production of anti-inflammatory cytokines transforming growth
factor-␤ and IL-10 concomitant with the down-regulation of the
proinflammatory cytokines TNF-␣ and IL-1 in mouse macrophages12 and epithelial cells.25 Endothelial cells appear to synthesize and release many proinflammatory and anti-inflammatory
cytokines including IL-1, IL-6, IL-8, and ET-1.54,55 Thus, an
additional role for endothelial PSR in the microvasculature could
be the modulation of the inflammatory phenotype especially in
disease states where the combination of adhesion and inflammation
are a particularly potent mix in relation to vascular and organ
dysfunction.48,56-58
In summary, we demonstrated the presence of a receptor for
phosphatidylserine, PSR, on the surface of human microendothelial
cells using both antigen expression and mRNA analysis. While
PSR is not constitutively expressed, its expression can be induced
on the surface of microendothelium by relevant agonists such as
LPS, cytokines, hypoxia, and heme. PSR is involved in mediating
direct interaction of PS-positive erythrocytes with microendothe-
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lial cells. The in vivo significance of these interactions requires
further studies in relevant disease models.
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